---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-336780"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2026-08-06T11:52:23+00:00"
generated_at: "2026-08-06T11:55:07.598377+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Agenus Q2 revenue $34.5M; $85M placement funds Phase 3 ROBBIN trial in MSS colon cancer

## Summary
- Q2 total revenue $34.5M (up from $25.7M YoY); pre-commercial product revenue $6.4M.
- Completed $85M private placement in July; warrants could add up to $255M.
- Phase 3 ROBBIN trial of BOT+BAL in neoadjuvant MSS colon cancer to start Q1 2027; targets 38,000 US patients annually.
- Discontinued funding for BATTMAN Phase 3 study (CCTG sponsored) to prioritize ROBBIN.
- Near-term milestones: NEST/UNICORN manuscripts H2 2026; corporate webcast Sept 10.

## SEC filing metadata
- accession: 0001193125-26-336780
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2026-08-06T11:52:23+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000119312526336780/0001193125-26-336780-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000119312526336780/agen-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-336780
- JSON: https://secwatch.observer/filing/0001193125-26-336780.json
- Plain text: https://secwatch.observer/filing/0001193125-26-336780.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.